[go: up one dir, main page]

MA31160B1 - Composé 3-substitue-[1,2,3]benzotriazinone pour améliorer les réponses synaptiques glutamatergiques. - Google Patents

Composé 3-substitue-[1,2,3]benzotriazinone pour améliorer les réponses synaptiques glutamatergiques.

Info

Publication number
MA31160B1
MA31160B1 MA32135A MA32135A MA31160B1 MA 31160 B1 MA31160 B1 MA 31160B1 MA 32135 A MA32135 A MA 32135A MA 32135 A MA32135 A MA 32135A MA 31160 B1 MA31160 B1 MA 31160B1
Authority
MA
Morocco
Prior art keywords
glutamerge
benzotriazinone
qualifies
answers
posture
Prior art date
Application number
MA32135A
Other languages
Arabic (ar)
English (en)
Inventor
Alexis Cordi
Gary Rogers
Rudolf Mueller
Original Assignee
Cortex Pharma Inc
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortex Pharma Inc, Servier Lab filed Critical Cortex Pharma Inc
Publication of MA31160B1 publication Critical patent/MA31160B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne la prévention et le traitement de l'insuffisance cérébrale, en particulier l'amélioration du fonctionnement de récepteur des synapses des réseaux cérébraux responsables de comportements d'ordre supérieur. Lesdits réseaux cérébraux sont impliqués dans des capacités cognitives en rapport avec un handicap de la mémoire observés dans un certain nombre de démences et dans des déséquilibres de l'activité neuronale entre différentes régions cérébrales ou supposés dans des troubles tels que la maladie de parkinson, la schizophrénie et les troubles affectifs. Selon un développement particulier, la présente invention concerne un composé utile dans le traitement de tels états et un procédé d'utilisation de ce composé dans un tel traitement.
MA32135A 2007-01-03 2009-07-31 Composé 3-substitue-[1,2,3]benzotriazinone pour améliorer les réponses synaptiques glutamatergiques. MA31160B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87850307P 2007-01-03 2007-01-03
US92143307P 2007-04-02 2007-04-02
PCT/US2007/026416 WO2008085506A1 (fr) 2007-01-03 2007-12-28 Composé de [1,2,3]-benzotriazinone 3-substituée destiné à améliorer les réponses synaptiques glutamatergiques

Publications (1)

Publication Number Publication Date
MA31160B1 true MA31160B1 (fr) 2010-02-01

Family

ID=39608956

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32135A MA31160B1 (fr) 2007-01-03 2009-07-31 Composé 3-substitue-[1,2,3]benzotriazinone pour améliorer les réponses synaptiques glutamatergiques.

Country Status (37)

Country Link
US (1) US8173644B2 (fr)
EP (1) EP2144506B1 (fr)
JP (1) JP5139446B2 (fr)
CN (1) CN101616592B (fr)
AP (1) AP2502A (fr)
AR (1) AR064740A1 (fr)
AT (1) ATE527269T1 (fr)
AU (1) AU2007342365B2 (fr)
BR (1) BRPI0720749A2 (fr)
CA (1) CA2674460C (fr)
CR (1) CR10906A (fr)
CU (1) CU23804B7 (fr)
CY (1) CY1112493T1 (fr)
DK (1) DK2144506T3 (fr)
EA (1) EA017437B1 (fr)
EC (1) ECSP099499A (fr)
ES (1) ES2374995T3 (fr)
GE (1) GEP20125438B (fr)
GT (1) GT200900189A (fr)
HN (1) HN2009001268A (fr)
HR (1) HRP20110970T1 (fr)
IL (1) IL199651A (fr)
MA (1) MA31160B1 (fr)
ME (1) ME00819B (fr)
MX (1) MX2009007242A (fr)
MY (1) MY154877A (fr)
NI (1) NI200900131A (fr)
NZ (1) NZ578293A (fr)
PL (1) PL2144506T3 (fr)
PT (1) PT2144506E (fr)
RS (1) RS52108B (fr)
SG (1) SG163545A1 (fr)
SI (1) SI2144506T1 (fr)
SV (1) SV2009003322A (fr)
TN (1) TN2009000277A1 (fr)
WO (1) WO2008085506A1 (fr)
ZA (1) ZA200904826B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100041647A1 (en) * 2007-01-03 2010-02-18 Cortex Pharmaceuticals, Inc. 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses
CA2685858C (fr) * 2007-05-17 2015-11-24 Cortex Pharmaceuticals, Inc. Amides disubstitues servant a ameliorer les reactions des synapses glutamatergiques
AU2008287445A1 (en) 2007-08-10 2009-02-19 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
US8168632B2 (en) 2007-08-10 2012-05-01 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for the treatment of respiratory disorders
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
WO2013075624A1 (fr) 2011-11-22 2013-05-30 北京哈三联科技股份有限公司 Inhibiteur de recaptage de glycine et son utilisation
FR3019464B1 (fr) 2014-04-07 2016-05-06 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
FR3034019B1 (fr) * 2015-03-26 2017-03-17 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
TN2017000508A1 (en) 2015-06-26 2019-04-12 Takeda Pharmaceuticals Co 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
CN106226509B (zh) * 2016-08-12 2019-09-06 中国人民解放军第四军医大学 一种在小鼠前扣带回皮层诱发dse现象的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723436A (en) * 1971-02-25 1973-03-27 Sun Oil Co Process for aromatic lactams
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
FR2597103B1 (fr) * 1986-04-15 1988-12-16 Provesan Sa Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde
PT651746E (pt) 1992-07-24 2002-09-30 Univ California Drogas que intensificam as respostas sinapticas mediadas por receptores de ampa
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
EP0709384B1 (fr) * 1994-10-31 1998-12-23 MERCK PATENT GmbH Dérivés de benzylpiperidine ayant une haute affinité pour les sites de liaison de récepteurs d'aminoacides
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US6030968A (en) 1996-09-17 2000-02-29 The Regents Of The University Of California Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
ZA991301B (en) 1998-02-18 1999-09-13 Neurosearch As Glutamate receptor modulators.
US6713474B2 (en) * 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6303542B1 (en) * 2000-08-18 2001-10-16 Rohm And Haas Company Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones
JP4620349B2 (ja) * 2001-11-26 2011-01-26 コーテックス ファーマシューティカルズ， インコーポレイテッド グルタメートシナプシス応答向上のためのカルボニルベンゾキサジン化合物
JP2003238555A (ja) * 2002-02-20 2003-08-27 Sumitomo Pharmaceut Co Ltd 細胞死抑制剤
AUPS255202A0 (en) 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
WO2004062616A2 (fr) * 2003-01-13 2004-07-29 Cortex Pharmaceuticals, Inc. Methode de traitement du declin cognitif du au manque de sommeil et au stress
GB0317482D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US20100041647A1 (en) * 2007-01-03 2010-02-18 Cortex Pharmaceuticals, Inc. 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses
CA2685858C (fr) * 2007-05-17 2015-11-24 Cortex Pharmaceuticals, Inc. Amides disubstitues servant a ameliorer les reactions des synapses glutamatergiques
AU2008287445A1 (en) 2007-08-10 2009-02-19 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
JP2010540436A (ja) 2007-09-20 2010-12-24 コーテックス ファーマシューティカルズ， インコーポレイテッド グルタミン酸作動性シナプス反応を増大するための３−置換１，２，３−トリアジン−４−オン及び３−置換１，３−ピリミジン−オン

Also Published As

Publication number Publication date
CU23804B7 (es) 2012-03-15
US8173644B2 (en) 2012-05-08
CA2674460A1 (fr) 2008-07-17
JP5139446B2 (ja) 2013-02-06
HK1140105A1 (en) 2010-10-08
AU2007342365B2 (en) 2012-11-15
MX2009007242A (es) 2009-09-02
HN2009001268A (es) 2011-12-27
US20100137295A1 (en) 2010-06-03
CN101616592A (zh) 2009-12-30
EA200900925A1 (ru) 2009-12-30
PL2144506T3 (pl) 2012-04-30
EA017437B1 (ru) 2012-12-28
AP2502A (en) 2012-10-23
ES2374995T3 (es) 2012-02-23
SI2144506T1 (sl) 2012-01-31
WO2008085506A1 (fr) 2008-07-17
CA2674460C (fr) 2014-07-15
IL199651A (en) 2015-08-31
GT200900189A (es) 2011-08-02
SV2009003322A (es) 2010-02-05
EP2144506A1 (fr) 2010-01-20
CY1112493T1 (el) 2015-12-09
SG163545A1 (en) 2010-08-30
HRP20110970T1 (hr) 2012-01-31
EP2144506B1 (fr) 2011-10-05
CN101616592B (zh) 2013-06-05
NZ578293A (en) 2012-01-12
ZA200904826B (en) 2010-09-29
TN2009000277A1 (en) 2010-10-18
EP2144506A4 (fr) 2010-05-05
CR10906A (es) 2009-10-23
ATE527269T1 (de) 2011-10-15
GEP20125438B (en) 2012-03-26
AP2009004931A0 (en) 2009-08-31
AR064740A1 (es) 2009-04-22
PT2144506E (pt) 2011-12-21
RS52108B (sr) 2012-08-31
DK2144506T3 (da) 2012-03-05
IL199651A0 (en) 2010-04-15
NI200900131A (es) 2010-03-11
MY154877A (en) 2015-08-14
AU2007342365A1 (en) 2008-07-17
BRPI0720749A2 (pt) 2014-01-14
CU20090117A7 (es) 2011-10-05
JP2010514838A (ja) 2010-05-06
ME00819B (fr) 2012-03-20
ECSP099499A (es) 2009-10-30

Similar Documents

Publication Publication Date Title
MA31160B1 (fr) Composé 3-substitue-[1,2,3]benzotriazinone pour améliorer les réponses synaptiques glutamatergiques.
MA31159B1 (fr) Composés [1,2,3]benzotriazinone substitués en position 3 destinés à améliorer les réponses synaptiques glutamatergiques
Liu et al. The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia
NO20064726L (no) Imidazolforbindelser for behandling av neurodegenerative forstyrrelser
MA34922B1 (fr) Imidazo[5,1-f][1,2,4] triazines pour le traitement de troubles neurologiques
TN2014000424A1 (fr) Agents pour le traitement de troubles impliquant la modulation des recepteurs de la ryanodine
MA34898B1 (fr) Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques
US20120171125A1 (en) Methods for Enhancing the Cognitive Function
MA32374B1 (fr) Composes comprenant un groupe cyclobutoxy
JP2009537568A5 (fr)
Sanchez-Todo et al. Fast Interneuron Dysfunction in Laminar Neural Mass Model Reproduces Alzheimer’s Oscillatory Biomarkers
TNSN08138A1 (fr) Derives d'imidazole pour le traitement de troubles neurologiques
GEP20063859B (en) Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
MA30661B1 (fr) Derives de n-phenyl-prenylamine pour le traitement de maladies ou troubles cognitifs, neurodegeneratifs ou neuronaux.
WO2005095348A3 (fr) Composes pyrazole-amines utilises dans le traitement des troubles neurodegeneratifs
UA93306C2 (ru) Соединение 3-замещенного-[1,2,3]-бензотриазинона для улучшения глутаматергических синаптических реакций
Seeman et al. Schizophrenia and the supersensitive synapse
McCabe Advances in the pharmacological treatment of bipolar affective disorders
CAZZULLO COGNITIVE IMPAIRMENT IN PHYSIOLOGICAL AND PATHOLOGICAL AGING
WO2005060517A3 (fr) Genes regules conjointement par differentes classes d'antidepresseurs
TH86961A (th) สารรักษาโรค